login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Heart failure patients benefit from MitraClip therapy, PERMIT-CARE trial shows


Wednesday, 05 Oct 2011 14:41
Angelo Auricchio
Angelo Auricchio


Results of an observational study presented at the European Society of Cardiology meeting in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular remodeling in patients with mitral regurgitation, who do not respond to cardiac resynchronisation therapy (CRT).


The trial, called PERMIT-CARE, is an investigator-led study evaluating the safety and efficacy of MitraClip treatment in 51 patients with clinically significant functional mitral regurgitation at seven European centres. All patients had unchanged symptoms and unchanged left ventricular volumes after at least six months of CRT. Nearly all patients enrolled in the study were considered ineligible for mitral valve surgery due to a high estimated mortality risk.


Results of the study demonstrate that functional mitral regurgitation reduction with MitraClip treatment is feasible, safe, and leads to substantial improvement in NYHA functional class and reverse left ventricular remodeling in approximately 70% of patients.


“Results of this study suggest that MitraClip treatment could offer, for the first time, a solution for heart failure patients who have severe mitral regurgitation and are unresponsive to CRT,” said Angelo Auricchio, the study’s lead investigator, of the Division of Cardiology at the Fondazione Cardiocentro Ticino in Lugano, Switzerland. “Surgery is not a good option for these patients because of their advanced left ventricular dysfunction and low ejection fraction. We have shown that they were significantly improved following treatment with the MitraClip device. I look forward to additional prospective studies to confirm our findings and to evaluate appropriate timing of MitraClip treatment in heart failure patients.” 


MitraClip
MitraClip

Severe functional mitral regurgitation is common in heart failure patients, including approximately one-third of those indicated for CRT therapy. CRT often reduces mitral regurgitation; however, mitral regurgitation has been reported to persist in about 20–25% of CRT treated patients, and in an additional 10–15% mitral regurgitation may actually worsen after CRT treatment.


Results of the study will be published in an upcoming issue of the Journal of the American College of Cardiology. The MitraClip system is designed to reduce significant mitral regurgitation by clipping together the leaflets of the mitral valve, one of the four valves of the heart. The catheter-based MitraClip device is delivered to the heart through the femoral vein, a blood vessel in the leg. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. After treatment, patients are usually home within two to three days and have been observed to recover quickly. The safety and efficacy of the MitraClip system were evaluated in the EVEREST II randomised clinical trial.



Add New Comment

Related Items


Most popular


Merit Medical Systems launches the Prelude Snap splittable sheath introducer
Wednesday, 03 Jun 2015
Merit Medical Systems has launched the Prelude Snap splittable sheath introducer, the design of which is based directly on physician feedback. Merit Medical Systems launches the Prelude Snap splittable sheath introducer

Men believe “long working hours” stop women from being interventional cardiologists
Wednesday, 15 Jul 2015
According to a new survey published in EuroIntervention, men state that the long working hours and the need to be on call that is associated with being an interventional cardiologist are the key ... Men believe “long working hours” stop women from being interventional cardiologists

Boston Scientific launches bioresorbable scaffold trial
Monday, 20 Jul 2015
Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess ... Boston Scientific launches bioresorbable scaffold trial

Features


Strut coverage: Optical coherence tomography and new stent technologies
Monday, 20 Jul 2015
Tim Kinnaird explores the risk of stent thrombosis with current technologies, how new technologies may be able to reduce this risk, and how OCT can help to assess this risk. Strut coverage: Optical coherence tomography and new stent technologies

The second generation of drug-eluting stents with biodegradable polymers may have potential advantages
Monday, 06 Jul 2015
Drug-eluting stents with biodegradable polymers have theoretical advantages over drug-eluting stents with permanent polymers—even second-generation drug-eluting stents. The second generation of drug-eluting stents with biodegradable polymers may have potential advantages

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions